NEW YORK (GenomeWeb) — Maverix Biomics and Diagnomics announced today that they have received CLIA validation for their next-generation sequencing pre-natal test on the Maverix Dx platform.

The test, called Non-Invasive Chromosome Examination (NICE), was developed by Diagnomics and the Eone-Diagnomics Genome Center, a joint venture between Diagnomics and the Eone Life Science Institute. It uses NGS to detect fetal chromosome aneuploidies in cell-free DNA, the companies said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.